Non Small Cell Lung Cancer - MRT-2359 - MYCL expression

Association details:

Biomarker:	MYCL expression
Cancer:	Non Small Cell Lung Cancer
Drug:	MRT-2359 (GSPT1 degrader)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: B - Late Trials

Source:

Monte Rosa Therap Press Release

Title:

Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023

Published date:

01/09/2023

Excerpt:

MRT-2359 received Fast Track designation from the FDA for the treatment of patients with previously treated, metastatic non-small cell lung cancer (NSCLC) with L-MYC or N-MYC expression.